Efficacy and Safety of Phentermine/Topiramate in Adults with Overweight or Obesity: A Systematic Review and Meta‐Analysis

Objective The study objective was to examine the association between phentermine/topiramate therapy and weight loss adverse events in adults with overweight or obesity by meta-analysis systematic review. Methods Medical Subject Headings free-text terms were selected search for eligible trials PubMed, Cochrane Central Register of Controlled Trials (CENTRAL), Embase up April 18, 2020. quality randomized controlled evaluated risk-of-bias tool. Meta-analysis performed using random-effect models. Results Phentermine/topiramate resulted an average 7.73 kg (95% CI: 6.60-8.85) general compared placebo. related dose phentermine/topiramate. Compared placebo, 3.55 2.22-4.88) 3.75/23 mg, 7.27 6.40-8.13) 7.5/46 8.25 6.92-9.79) 15/92 mg. For participants different weight-loss subgroups, ≥5%, ≥10%, ≥15% baseline 3.18 2.75-3.67), 5.32 4.53-6.25), 5.65 3.55-9.01), respectively. associated treatment mainly included dysgeusia (odds ratio [OR] = 8.86, 95% 5.65-13.89), paresthesia (OR 8.51, 6.20-11.67), dry mouth 6.71, 5.03-8.94), disturbance attention 4.48, 2.39-8.41), irritability 4.10, 2.29-7.33), hypoesthesia 3.81, 1.32-11.00), constipation 2.43, 2.02-2.93), dizziness 2.26, 1.72-2.98). also reduced waist circumference, blood pressure, sugar levels, lipid levels. Conclusions has considerable benefit reducing body weight, efficacy closely dosage. However, it increased risk nervous system-related events.